## Abstract Immunologic markers associated with hepatitis B virus (HBV) infection (HBsAg, antiβHBs, HBeAg, antiβHBe, antiβHBc, antiβΞ΄) were tested by radioimmunoassay of serum from chronic hepatitis patients. The corresponding liver biopsy samples were examined for the presence of HBsAg, HBcAg, and
The immune response of healthy adults to a reduced dose of hepatitis B vaccine
β Scribed by Wolf Szmuness; Cladd E. Stevens; Edward J. Harley; Edith A. Zang; Patricia E. Taylor; Harvey J. Alter; The Dialysis Vaccine Trial Group
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 592 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Three hundred thirtyβsix medical personnel from hemodialysis centers were treated with three doses, 20 ΞΌg each, of the Merck hepatitis B vaccine (at 0, 1, and 6 months). Within 1 month after the first injection, 41% converted to antiβHBs positivity; after the second injection the conversion rate rose to 80β90%; and after the booster, to 96β98%. The later rate remained unchanged during the 18βmonth followβup period. Only 2.8% of those vaccinated did not respond to the vaccine. The patterns of immune responses to 20βΞΌg doses were found to be exactly the same as to 40βΞΌg doses. It is suggested that reduced doses of vaccine should be as efficacious as the larger ones.
π SIMILAR VOLUMES
The immunogenic effect of hepatitis B vaccine (H-B-vax) was evaluated in 120 seronegative healthy Nigerians. Three doses of the vaccine were given at 0, 1, and 6 months. Serial blood samples were tested I month after each vaccination for hepatitis B surface antibody (anti-HBs) and antibody to hepati
Nineteen healthy young adults were vaccinated with plasma-derived hepatitis B vaccine at months 0, 1, and 12, and their immune responses were compared to those of a similar group of 20 vaccinees immunized at months 0, 1, and 6. Late booster injections at 12 months produced nearly fivefold higher geo
newborn infants of 79 hepatitis B surface antigen (HBsAg)-positive women were enrolled in a study of the efficacy of hepatitis B immune globulin (HBIG) in the prophylaxis of perinatal transmission of hepatitis B virus (HBV) infection. HBIG 0.5 ml or 0.25 ml was given to the newborn within 15 minutes